Ignite Creation Date:
2025-12-25 @ 12:02 AM
Ignite Modification Date:
2026-02-20 @ 3:33 PM
Study NCT ID:
NCT04081558
Status:
COMPLETED
Last Update Posted:
2025-08-29
First Post:
2019-09-04
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Electronic Symptom Follow-up of Cancer Patients
Sponsor:
Oulu University Hospital
Organization:
Study Overview
Official Title:
Follow-up of Cancer Patients Receiving Chemotherapy or Targeted Therapy by Electronic Patient Reported Outcomes-tool
Status:
COMPLETED
Status Verified Date:
2025-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Use of ePROs in oncological care have resulted in improvement of QoL, decreased ER visits, and improvement of overall survival. Furthermore, ePRO follow-up resulted in better QoL, improved ECOG status and more active cancer treatments at disease relapse, and improved survival among cancer survivals. The current study investigates electronic patient reported outcome tool in the follow-up of cancer patients receiving chemotherapies or targeted therapies.
The aims of the current study are: 1) The number of alerts triggered by Kaiku Cancer medical treatment side-effects questionnaire and their correlation to treatment side-effects, other relevant medical events, tumor progression, and survival 2) Changes in Kaiku QLQ-C30 QoL questionnaire and their correlation to cancer treatment response, side-effects, other relevant medical event or survival 3) Patient compliance to Kaiku ePRO surveillance during treatment period according to response rates of Patient experience survey, Kaiku Cancer medical treatment side-effects questionnaire and Kaiku QLQ-C30 QoL questionnaire
In addition, in the CRC (colorectal cancer) cohort:
1. Integration of laboratory values to patient reported symptoms when prescribing a new chemotherapy cycle
2. Number of phone calls related to prescribing a new chemotherapy cycle
3. Unscheduled doctor appointments in oncology unit
4. ER visits
5. Days in hospitalization
6. Unscheduled investigations in health care
7. Development of peripheral neurotoxicity
8. The number of chemotherapy dose reductions
9. The number of chemotherapy delays
10. Health care user experience survey
The aims of the current study are: 1) The number of alerts triggered by Kaiku Cancer medical treatment side-effects questionnaire and their correlation to treatment side-effects, other relevant medical events, tumor progression, and survival 2) Changes in Kaiku QLQ-C30 QoL questionnaire and their correlation to cancer treatment response, side-effects, other relevant medical event or survival 3) Patient compliance to Kaiku ePRO surveillance during treatment period according to response rates of Patient experience survey, Kaiku Cancer medical treatment side-effects questionnaire and Kaiku QLQ-C30 QoL questionnaire
In addition, in the CRC (colorectal cancer) cohort:
1. Integration of laboratory values to patient reported symptoms when prescribing a new chemotherapy cycle
2. Number of phone calls related to prescribing a new chemotherapy cycle
3. Unscheduled doctor appointments in oncology unit
4. ER visits
5. Days in hospitalization
6. Unscheduled investigations in health care
7. Development of peripheral neurotoxicity
8. The number of chemotherapy dose reductions
9. The number of chemotherapy delays
10. Health care user experience survey
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: